Close

Techno Trends

Syntegon with stable business development in 2022

Syntegon looks back on a stable business development in 2022. Thanks to its proven machinery and service portfolio, innovative powers, and global footprint with 37 sites in 20 countries, the company increased both order income and sales last year...

The Importance of Relationships in the Rare Disease Community

In my role as CRO Partner Manager, I’m responsible for working with some of the industry’s largest contract research organizations to implement patient convenience programs. With an increasing focus on what’s needed to recruit and retain participants in clinical...

Lubrizol launches technology to simplify manufacturing of parenteral drugs

Lubrizol Life Science (LLS) Health has launched Apisolex, a solubility-enhancing excipient for use in parenteral drug products. This technology overcomes solubility hurdles that challenge existing excipients or manufacturing techniques. At present, 60-90% of potential new active pharmaceutical ingredients (APIs) in...

COVID-19 And Collaborative Approach of Research And Health

Although we cannot say that it was unheard of, collaboration on the basis of interdisciplinary and interprofessional elements has always been crucial in any research and care-based setting. And why not; when there are experts coming from varied specialized...

Recent Trends & Opportunities in Digital Therapeutics Industry: The Future of Healthcare

Digital therapeutics is a branch of digital health that is the amalgamation of innovative technologies, services, and products for healthcare and wellness. Digital therapeutics are used independently or in the combination with medical devices, therapies medications are optimized according...

‘Supply Chain Trends in Pharma 2021’?

According to Marcelo Cruz, Director Business Development and Marketing at Tjoapack One of the key trends transforming the pharmaceutical industry in recent years has been the growth of biopharma products to treat chronic diseases, such as diabetes. This will continue in...

There Is A Lot In Store For Big Pharma

The Big Pharma is expecting higher gains in 2021, and surprisingly, this is not because of COVID-19. Focus on the anti-inflammatory and diabetes drugs has kept the spirits high with new clinical data being given a lot of thrust....

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read